drugset / Trial / NCT03452072

Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds

NCT03452072 ↗

Phase 2/3 Completed 87 enrolled Brigham and Women's Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 114 patients who have their skin cancer surgically removed resulting in open surgical wounds less or equal to 1.5 cm. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in open surgical wounds less or equal to 1.5 cm.

Timeline

Start
2018-08-20
Primary completion
2020-12-29
Completion
2021-06-30

Outcome

Missed primary endpoint

registry analysis (other test); 0.25% Timolol Gel Under the Paraffin Gauzes vs Standard of Care Dressings; p = 0.580 NCT03452072 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Timolol Other / unclassified 0.25 % Topical

Indications

No indication recorded.